GlobeNewswire·Jun 11, 2026, 8:30 AM ET

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

RNXT

RenovoRx, Inc. (NASDAQ: RNXT) announced the publication of a peer-reviewed case study in Radiology Case Reports by Moffitt Cancer Center researchers regarding the optimization of TAMP procedures using RenovoCath.
The study details the first successful use of coil plus glue embolization to isolate a pancreaticoduodenal artery side branch, enabling targeted intra-arterial gemcitabine delivery for a patient with locally advanced pancreatic cancer (LAPC).
An 82-year-old patient with unresectable LAPC completed eight RenovoCath-enabled TAMP treatments without complications following stereotactic body radiation therapy.
Four-month follow-up imaging showed stable tumor size on CT scans but a 52% reduction in tumor metabolic activity on PET-CT, suggesting PET imaging may improve monitoring of therapeutic response compared to CT alone.
Ramtin Agah, RenovoRx's Chief Medical Officer, stated the findings support the procedural flexibility of the TAMP platform and demonstrate how anatomical challenges can be addressed to optimize targeted therapy.
RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025 and a record $563,000 in the first quarter of 2026 while expanding orders to National Cancer Institute-designated centers.
The company is evaluating its drug-device combination candidate IAG in the Phase III TIGeR-PaC trial, anticipating full enrollment in June 2026 and final data readout in mid-to-late 2027.
IAG received Orphan Drug Designation for pancreatic cancer and bile duct cancer, granting seven years of market exclusivity upon FDA approval.
RenovoCath is an FDA-cleared device intended for blood flow isolation and delivery of therapeutic agents, while IAG remains under investigation and is not yet approved for commercial sale.